P398 Clinical course of ulcerative colitis and disease extension the follow-up study in patients with distal ulcerative colitis

Abstract

mild hypotension. On the other hand, 21 patients passed from Phase2 to Phase3 schedule. The comparative analysis showed no significant differences between 1 h and 30-min infusions regarding the presence of mild adverse events (2.6 vs 1.6%; p = 0.963) and hypotension reactions (34.6 vs 21.8%; p = 0.065). GEE models showed an OR for the 30min vs 1 h-infusion of 1.33 (CI95%: 0.14 12.3) when considering mild reactions and 0.74 (CI95%: 0.38 1.42) when considering mild hypotension. Conclusions: Accelerate infusion-protocols of IFX is feasible and safe. However, mild adverse events can occur and they are more frequent in accelerated infusion-protocols but they don’t require stopping or modifying IFX therapy. Future costeffective analyses are needed in order to confirm the benefits of this alternative.